Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bleomycin sclerotherapy for symptomatic liver hemangioma
IRCT20191106045354N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bleomycin in liver hemangioma (HH), sponsored by Tehran University of Medical Sciences. Primary endpoints: Change in pain score, Incidence of intra-peritoneal hematoma and 2 more. Started Sep 2018; status: completed.
02
Drugs
bleomycin
03
Conditions
liver hemangioma (HH)
Beyond the preview
Go deeper on IRCT20191106045354N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191106045354N1.